Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia
Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia
复制标题
DOI：
10.1182/blood.2019000402
复制
发表时间：
2019-10-03
期刊：
影响因子：
20.3
通讯作者：
Dearden, Claire
中科院分区：
文献类型：
--
作者：
Staber, Philipp B.;Herling, Marco;Dearden, Claire
t细胞前淋巴细胞白血病（T-PLL）是一种罕见的成熟t细胞肿瘤，具有异质性的临床病程。随着新的治疗方案的出现，可能会改变T-PLL患者的管理，有必要为临床试验的设计和实施制定一致的指导方针。T-PLL国际研究组（TPLL-ISG）着手定义诊断、治疗指征和疗效评估的标准化标准。这些标准将促进T-PLL临床试验结果的比较，从而支持临床决策，以及卫生保健当局批准新疗法。
T-cell prolymphocytic leukemia (T-PLL) is a rare, mature T-cell neoplasm with a heterogeneous clinical course. With the advent of novel treatment options that will potentially change the management of patients with T-PLL, it has become necessary to produce consensus guidelines for the design and conduct of clinical trials. The T-PLL International Study group (TPLL-ISG) set out to define standardized criteria for diagnosis, treatment indication, and evaluation of response. These criteria will facilitate comparison of results from clinical trials in T-PLL, and will thus support clinical decision making, as well as the approval of new therapeutics by healthcare authorities.